# Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

> **NCT03030183** · PHASE2 · COMPLETED · sponsor: **Ra Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Zilucoplan (RA101495)

## Key facts

- **NCT ID:** NCT03030183
- **Lead sponsor:** Ra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-17
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03030183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03030183, "Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03030183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*